Skip to main
ARTV
ARTV logo

ARTV Stock Forecast & Price Target

ARTV Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artiva Biotherapeutics Inc. is advancing a promising pipeline of allogeneic NK cell therapies aimed at treating hematologic malignancies and solid tumors, with several ongoing trials demonstrating initial safety and efficacy results. The company recently received FDA fast track designation for its lead candidate, AlloNK, which is expected to enhance clinical development efficiency and expedite regulatory processes. Financially, Artiva is in a solid position with $166 million in cash and equivalents as of Q1 2025, positioning it well to sustain operations and support critical milestones through 2027.

Bears say

Artiva Biotherapeutics Inc is facing a challenging outlook, primarily due to concerns regarding the efficacy and safety of its lead candidate, AlloNK, which could necessitate a significant reduction in the probability of success if initial data in 1H:25 fails to demonstrate deep B-cell aplasia or tolerability. Additionally, the company may need approximately $450 million in additional financing through 2040, raising questions about its ability to sustain operations, especially given the potential for decreased commercial viability amid competitive pressures and regulatory uncertainties. The overall assessment reflects apprehensions about the pipeline's ability to produce successful clinical candidates, alongside data showing limited efficacy of current treatments in ongoing trials.

ARTV has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artiva Biotherapeutics Inc (ARTV) Forecast

Analysts have given ARTV a Buy based on their latest research and market trends.

According to 4 analysts, ARTV has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artiva Biotherapeutics Inc (ARTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.